Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

Exclusion Criteria

• •1. The participants are diagnosed with prostate cancer before this study.
• •2. The participants have received any related treatment for prostate cancer.
• •3. The participants have chronic prostatitis.
• •4. The participants' serum hemoglobin lowers than 10 mg/dl within 1 month.
• •5. The participants' serum platelet lowers than 15 103/uL within 1 month.
• •6. The participants' serum prothrombin time (PT) is prolonged longer than 1.2-fold within 1 month.
• •7. The participants' serum active partial prothrombin time (aPPT) is prolonged longer than 45 seconds within 1 month.
• •8. The participants have hemorrhagic disease such as Hemophilia, Von Willebrand disease, thrombocytopenia, systemic Lupus Erythematosus, etc. within 6 months.
• •9. The participants have conditions of poor immunity status such as HIV infection, receiving treatment for other cancer, DM poor control, use of immunomodulator (ex.
• •steroid, etc.) within 6 months.
• •10. The participants have hypertension poor control that is BP cannot be controlled lower than 140/90mmHg whether or not taking medication within 6 months.
• •11. The participants have suffered from CVA including infarctions and hemorrhages within 6 months.
• •12. The participants have suffered from angina including stable and unstable types within 6 months.
• •13. The participants have suffered from arrythmia poor control within 6 months.
• •14. The participants have suffered from liver dysfunction such as AST/ALT ratio \>2、total bilirubin \>1.5 mg/dL within 6 months.
• •15. The participants are allergic to any radiopharmaceutical or imaging agent.
• •16. The participants suffered stage IV chronic kidney disease (eGFR\<30 mL/min/1.73 m2) within 6 months
• •17. The participants suffered acute kidney injury within 6 months.
• •18. The participants are absolute and relative contraindications to MRI examination.